Lebrikizumab
chemical compound
Lebrikizumab, sold under the brand name Ebglyss, is a humanized monoclonal antibody used for the treatment of atopic dermatitis (atopic eczema). It is an interleukin 13 antagonist. It is given by subcutaneous injection.
The most common side effects include injection site reactions, dry eye and conjunctivitis, including allergic conjunctivitis.
Lebrikizumab was approved for medical use in the European Union in November 2023, in Canada in June 2024, and in the US in September 2024.
Medical uses
Lebrikizumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents aged twelve years of age and older with a body weight of at least 40 kilograms (88 lb) who are candidates for systemic therapy.
Mechanism of action
Lebrikizumab blocks interleukin 13 (IL-13), a cytokine (cell-signalling protein) that is produced by a type of white blood cell called Th2 cells. IL-13 is thought to induce the expression of another signalling protein, periostin, by epithelial cells of the bronchi. Periostin in turn seems to partake in a number of asthma related problems, such as bronchial hyperresponsiveness, inflammation, and activation and proliferation of airway fibroblasts, which are involved in airway remodelling.
This theory is supported by the fact that people with high periostin levels responded significantly better to lebrikizumab in the phase II study: the forced expiratory volume in 1 second (FEV1) was 8.2% higher than under placebo in this group (measured from the respective baselines), while low-periostin participants had 1.6% higher FEV1, and the average value for all participants was 5.5%.
“Lebrikizumab” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Lebrikizumab, chemical and compound can confirm, complicate or overturn.
Why this record matters
“Lebrikizumab” is worth following because a concise public description often conceals a longer documentary argument. Here, Lebrikizumab, chemical and compound provides the most credible route into that argument.
The date and method of observation matter as much as the stated conclusion, especially where classification or consensus has changed. The source revision retrieved here is dated Mar 15, 2026. The linked authority identifier is Q3829321. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2023 and 2024.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Lebrikizumab”, its source revision and the description used here.
- Expand the search: follow Lebrikizumab primary sources, Lebrikizumab archive and Lebrikizumab research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Lebrikizumab”?
- Which observation, specimen, dataset or publication supports the account?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Lebrikizumab” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.